Maxygen Second Quarter 2008 Financial Results Conference Call Notice

Thursday, July 31, 2008, 4:30 p.m. ET
REDWOOD CITY, Calif.--(Business Wire)--
Maxygen, Inc. (Nasdaq:MAXY) will host a conference call to discuss
the company's second quarter 2008 financial results and business
updates at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, July 31, 2008.
Russell Howard, Maxygen's chief executive officer, will host the call.
A press release announcing Maxygen's second quarter 2008 financial
results will be issued that same day at approximately 4:00 p.m. ET
(1:00 p.m. PT).

Participants in the U.S. can access the call by dialing
866.202.4367 and using the passcode 62998376. International
participants can dial 617.213.8845 and use the same passcode. A live
webcast of the conference call will be available on the Maxygen web
site at www.maxygen.com/webcasts.

Telephone and webcast replays of the conference call will be
available until August 31, 2008. To access the telephone replay, dial
888-286-8010 (U.S.) or 617.801.6888 (international) and use the
passcode 37824983. To access the webcast archive, go to
www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing
improved versions of protein drugs. The company's lead program,
MAXY-G34, is designed to be an improved long-acting G-CSF for the
treatment of neutropenia. MAXY-G34 is currently in Phase II clinical
trials. Maxygen also has a MAXY-4 program, under which it is exploring
new CTLA4-Ig product candidates for the treatment of a broad array of
autoimmune disorders, including rheumatoid arthritis. Maxygen uses its
proprietary DNA shuffling technology and extensive protein
modification expertise to pursue the creation of biosuperior proteins.
www.maxygen.com

Maxygen, Inc.
Michele Boudreau, 650-279-2088
Investor and Public Relations
michele.boudreau@maxygen.com

Copyright Business Wire 2008